About CaReMeLO
Cardiac disease, chronic kidney and liver disease and metabolic derangements like type 2 diabetes (T2DM) and their risk factors share etiologies and pathophysiologic mechanisms. These novel insights and their therapeutic implications have been recognized and adopted by cardiology, nephrology and endocrinology alike. Yet a need exists for a multidisciplinary scientific platform that unites all interested parties and serves as a unique gathering, devoting time to in-depth Cardiovascular, Renal, Liver, Metabolic and Obesity discussions.
The conference will continue to spotlight the pivotal role of family physicians in the integrated management of cardio-renal-metabolic (CRM) syndrome, steatotic liver disease, and obesity (CaReMeLO), with an enhanced focus on the GLP-1R agonist such as Semaglutide 2,4 mg (Wegovy) and the dual GIPR/GLP-1R agonist -Tirzepatide (Mounjaro).
Conference Highlights
Expanded Sessions
Dedicated tracks on the use of GLP-1 receptor agonists, highlighting their clinical benefits, patient selection, and real-world application in treating obesity.
Collaborative Workshops
Sessions on fostering a multidisciplinary approach to patient care, featuring insights into successful collaboration between family physicians, endocrinologists, cardiologists, nephrologists, and allied health professionals.
Expert Insights
Hear from a distinguished panel of speakers, as well as leading family physicians on cardiometabolic health and the role of the family physician.
Innovative Learning
Case-based discussions, interactive workshops, and hands-on training sessions designed to enhance practical skills.
Networking
Ample opportunities for one-on-one interactions, group discussions, and partnership development, with a focus on fostering collaborations that transcend national borders within Europe.
In partnership with the
Polish Society of Family Medicine (PTMR)
